Su1810 Serum microRNA-34a: A Potential Biomarker for Liver Inflammation in Non-Alcoholic Fatty Liver Disease

2015 ◽  
Vol 148 (4) ◽  
pp. S-1056-S-1057
Author(s):  
Puth Muangpaisarn ◽  
kanisa Jampoka ◽  
Sunchai Payungporn ◽  
Naruemon Wisedopas ◽  
Chalermrat Bunchorntavakul ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Liver Inflammation ◽  
Alcoholic Fatty Liver ◽  
Serum Microrna ◽  
Potential Biomarker ◽  
Alcoholic Fatty Liver Disease

scholarly journals Bicyclol Regulates Hepatic Gluconeogenesis in Rats with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease by Inhibiting Inflammation

2021 ◽  
Vol 12 ◽  
Author(s):  
Hongxue Li ◽  
Qian Xu ◽  
Chengye Xu ◽  
Yuxin Hu ◽  
Xingyang Yu ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Liver Disease ◽  
Glucose Metabolism ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Glucose Metabolism Disorders ◽  
Liver Inflammation ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Hepatic gluconeogenesis plays an important role in maintaining the body’s glucose metabolism homeostasis. Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver diseases, when combined with type 2 diabetes mellitus (T2DM), it can cause severe glucose metabolism disorders. Studies have confirmed that chronic liver inflammatory lesions are the basis of T2DM combined with NAFLD (T2DM–NAFLD), inhibiting liver inflammation can improve glucose metabolism disorders. It is essential to explore safe and effective drugs to inhibit liver inflammation to improve the body’s glucose metabolism disorders. Bicyclol is a biphenyl derivative that has anti-oxidative and anti-inflammatory properties. In the present study, the hepatoprotective effects and underlying mechanisms of bicyclol in T2DM–NAFLD were investigated, and T2DM–NAFLD with/without bicyclol treatment models were established. The results revealed that bicyclol alleviated fasting blood glucose, serum transaminase levels, insulin resistance, hepatic adipogenesis, lipid accumulation and markedly reduced T2DM–NAFLD rat histological alterations of livers. Not only that, bicyclol markedly attenuated T2DM–NAFLD induced production of inflammation factors (IL-1β and TNF-α). Moreover, bicyclol suppressed the expression of insulin/gluconeogenesis signaling pathway (Akt, PGC-1α and PEPCK). These findings suggested that bicyclol might be a potentially effective drug for the treatment of T2DM–NAFLD and other metabolic disorders.

Combined Amelioration of Ginsenoside (Rg1, Rb1, and Rg3)-enriched Korean Red Ginseng and Probiotic Lactobacillus on Non-alcoholic Fatty Liver Disease

2019 ◽  
Vol 20 (3) ◽  
pp. 222-231 ◽  
Author(s):  
Jin-Chul Kim ◽  
Joo-Yeong Jeon ◽  
Woong-suk Yang ◽  
Cheorl-Ho Kim ◽  
Dae-Woon Eom
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Expression Patterns ◽  
Chow Diet ◽  
Liver Inflammation ◽  
Red Ginseng ◽  
Korean Red Ginseng ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Background: Red ginseng is a traditional medicine that has been used to treat numerous metabolic and inflammatory diseases. Probiotic administration has been established to have beneficial effects in non-alcoholic fatty liver disease (NAFLD). The purpose of this study was to determine whether a combination of Korean red ginseng (KRG) and probiotics could synergistically reduce NAFLD and liver inflammation compared with the effects reported for each individual product. Method: db/db and C57BL/6 mice were fed a normal chow diet and high-fat diet (HFD), respectively, and were treated with KRG, probiotics, or both. Samples were examined for lipid content, kinase protein phosphorylation, and gene expression patterns. Results: KRG- and probiotic-treated HFD-fed mice exhibited a reduction in body weight and a decrease in inflammatory cytokine secretion compared with the non-treated control mice. The same treatment was less successful in improving NAFLD parameters in the db/db mice while the combination of both products did not enhance their therapeutic potential. Conclusion: The results of this study indicate that KRG and probiotics administration ameliorated NAFLD symptoms in a mouse model of dyslipidemia by reducing weight gain and liver inflammation. Coadministration of both products did not enhance their efficacy, and further research should be conducted to clarify their mechanisms of action.

Dynamic FDG-PET study of liver inflammation in non-alcoholic fatty liver disease

2017 ◽  
Vol 66 (1) ◽  
pp. S592 ◽  
Author(s):  
G. Wang ◽  
M. Corwin ◽  
K. Olson ◽  
S. Stewart ◽  
C. Zha ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fdg Pet ◽  
Fatty Liver Disease ◽  
Liver Inflammation ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Serum periostin is a potential biomarker for non-alcoholic fatty liver disease: a case–control study

Endocrine ◽  
2015 ◽  
Vol 51 (1) ◽  
pp. 91-100 ◽  
Author(s):  
Jin-Zhou Zhu ◽  
Hua-Tuo Zhu ◽  
Yi-Ning Dai ◽  
Chun-Xiao Li ◽  
Zhi-Yun Fang ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Case Control Study ◽  
Case Control ◽  
Alcoholic Fatty Liver ◽  
Potential Biomarker ◽  
Serum Periostin ◽  
Alcoholic Fatty Liver Disease ◽  
Control Study

scholarly journals SCCA-IgM as a Potential Biomarker of Non-Alcoholic Fatty Liver Disease in Patients with Obesity, Prediabetes and Diabetes Undergoing Sleeve Gastrectomy

Obesity Facts ◽  
2019 ◽  
Vol 12 (3) ◽  
pp. 291-306
Author(s):  
Silvia Bettini ◽  
Emanuel Bordigato ◽  
Gabriella Milan ◽  
Chiara Dal Pra’ ◽  
Francesca Favaretto ◽  
...  
Keyword(s):  
Sleeve Gastrectomy ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Potential Biomarker ◽  
Alcoholic Fatty Liver Disease

Bacterial and eukaryotic extracellular vesicles and non-alcoholic fatty liver disease: new players in the gut-liver axis?

2021 ◽  
Author(s):  
Alexandre Villard ◽  
Jérôme Boursier ◽  
Ramaroson Andriantsitohaina
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Extracellular Vesicles ◽  
Fatty Liver Disease ◽  
Chronic Liver ◽  
Present Review ◽  
Liver Inflammation ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

The liver and intestine communicate in a bi-directional way through the biliary tract, portal vein, and other components of the gut-liver axis. The gut microbiota is one of the major contributors to the production of several proteins and bile acids. Imbalance in the gut bacterial community, called dysbiosis, participates in the development and progression of several chronic liver diseases, such as non-alcoholic fatty liver disease (NAFLD). NAFLD is currently considered the main chronic liver disease worldwide. Dysbiosis contributes to NAFLD development and progression, notably by a greater translocation of pathogen-associated molecular patterns (PAMPs) in the blood. Lipopolysaccharide (LPS) is a PAMP that activates toll-like receptor 4 (TLR4), induces liver inflammation, and participates in the development of fibrogenesis. LPS can be transported by bacterial extracellular vesicles (EVs). EVs are spherical structures produced by eukaryotic and prokaryotic cells that transfer information to distant cells and may represent new players in NAFLD development and progression. The present review summarizes the role of eukaryotic EVs, either circulating or tissue-derived, in NAFLD features, such as liver inflammation, angiogenesis, and fibrosis. Circulating EV levels are dynamic and correlate with disease stage and severity. However, scarce information is available concerning the involvement of bacterial EVs in liver disease. The present review highlights a potential role of bacterial EVs in insulin resistance and liver inflammation, although the mechanism involved has not been elucidated. Additionally, because of their distinct signatures, eukaryotic and prokaryotic EVs may also represent a promising NAFLD diagnostic tool as a "liquid biopsy" in the future.

Sign in / Sign up

Export Citation Format

Share Document